Preferences help
enabled [disable] Abstract
Number of results
2014 | 4 | 4 | A160-A164
Article title

IgM multiple myeloma: diagnostic difficulties and results of bortezomib treatment – case report

Title variants
Languages of publication
The IgM paraprotein secretion is most frequently associated with Waldenström’s macroglobulinemia. In very rare cases it may also occur in multiple myeloma. The diagnostic and therapeutic process of a 84 year old male suffering from IgM multiple myeloma is described, including difficulties in establishing this diagnosis. Due to infectious complications, after the first cycle of melphalan– prednisone–bortezomib treatment, melphalan was stopped, subsequently, bortezomib and prednisone doses were also reduced. Two treatment interruptions have occurred. Despite reduced treatment intensity, the patient was in very good partial remission, while the toxicity profile was acceptable. IgM multiple myeloma should be included in the differential diagnosis of IgM paraproteinemia, also when osteolytic lesions and translocation 11:14 are not detected. Bortezomib-based therapy can be effective in elderly patients (also in those suffering from cardiac insufficiency), even when dose reduction is required.
Physical description
  • Dmoszyńska A, Walter-Croneck A, Usnarska-Zubkiewicz L et al. Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2013. Acta Haematol Pol 2013; 44(1): 43-47.
  • Jurczyszyn A, Skotnicki AB. Szpiczak mnogi – kompleksowa diagnostyka i terapia. Górnicki Wydawnictwo Medyczne, Wrocław 2010.
  • Lech-Marańda E. Makroglobulinemia Waldenströma/chłoniak limfoplazmocytowy. W: Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych – pp. 2013 rok. Krzakowski M, Warzocha K (ed.). Via Medica, Gdańsk 2013.
  • Schuster SR, Rajkumar SV, Dispenzieri A et al. IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom’s macroglobulinemia. Am J Hematol 2010; 85(11): 853-855.
  • Higeta D, Yokohama A, Osaki Y et al. IgM-lambda multiple myeloma presenting with systemic amyloidosis. Rinsho Ketsueki 2009; 50(12): 1711-1714.
  • Willenbacher E, Erdel M, Strasser U et al. IgM myeloma: more on a rare entity. Br J Haematol 2008; 143(1): 146-148.
  • Fan J, Fu W, Shi H et al. Clinical and laboratory features of four cases with IgM multiple myeloma. Zhonghua Xue Ye Xue Za Zhi 2013; 34(4): 341-344.
  • Lin P, Hao S, Handy BC et al. Lymphoid neoplasms associated with IgM paraprotein: a study of 382 patients. Am J Clin Pathol 2005; 123(2): 200-205.
  • Feyler S, O’Connor SJM, Rawstron AC et al. IgM myeloma: a rare entity characterized by a CD20-CD56-CD117-immunophenotype and the t(11;14). Br J Haematol 2008; 140(5): 547-551.
  • An G, Xu Y, Shi L et al. T(11;14) Multiple Myeloma: a Subtype Associated With Distinct Immunological Features, Immunophenotypic Characteristics But Divergent Outcome. Leuk Res 2013; 37(10): 1251-1257.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.